The efficacy of the combination of CEA-TCB plus a PD-L1 blocking antibody was further assessed in fully immunocompetent model consisting of human CEA transgenic (huCEA Tg) C57BL/6J mice bearing a syngeneic colorectal tumor line (MC38) stably expressing human CEA (MC38-hCEA). The gene discussed is CEACAM5; the disease is colorectal neoplasm.